Navigation Links
Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
Date:9/17/2008

BRIDGEWATER, N.J., Sept. 17 /PRNewswire/ -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke. In this study, patients suffering acute ischemic stroke who were treated with Epoetin alfa within six hours of the onset of stroke symptoms died more frequently than patients receiving placebo. Ortho Biotech has reported this information to the U.S. Food and Drug Administration and to European regulatory authorities. Additional analyses are underway to better understand these preliminary results.

Epoetin alfa is marketed as EPREX(R) / ERYPO(R) outside the U.S. by Janssen-Cilag, as PROCRIT(R) in the U.S. by Ortho Biotech and as EPOGEN(R) in the U.S. by Amgen. None of these products are approved in any country for use in patients with acute ischemic stroke. Epoetin alfa is a member of the class of erythropoiesis-stimulating agents (ESAs). ESAs should be used strictly in accordance with their approved indications and dosing recommendations.

This investigator-initiated experimental study was designed and conducted by an investigator in Europe. Ortho Biotech provided study drug and funding, but the company had no role in designing or conducting the study. The investigator has informed the company that the results of this study will be submitted for publication promptly.


'/>"/>
SOURCE Ortho Biotech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... 21, 2014 When children go back to ... can cause them to become sick and risk missing school. ... to help them fight these germs to ensure a successful ... do just that with its XFactor program. , The XFactor ... chewable multi-vitamins. Children ages 4 and up can receive 30-day ...
(Date:8/21/2014)... 2014 Young girls with an intense, red, itchy ... increased risk of developing urinary tract infections (UTIs), according ... The treatment may be as simple as better hygiene ... swimming pools. , "Vulvitis is a common condition affecting ... Steve J. Hodges, M.D., associate professor of urology at ...
(Date:8/21/2014)... 21, 2014 Greater awareness among parents ... babies before they are full term has decreased the ... of the country, early elective deliveries (EEDs) still occur ... years, EED is defined as delivery before 39 weeks ... neonatal morbidity and mortality, and offers no benefit to ...
(Date:8/21/2014)... Steven Reinberg HealthDay ... An experimental drug shows promise in treating respiratory syncytial virus ... "We are finally making major progress in being able ... cause of serious viral pneumonia, second only to influenza virus," ... at the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... Indiana (PRWEB) August 21, 2014 ... employee benefits advisory organization, is pleased to announce ... Based in Knoxville, Tennessee, Trinity Benefit Advisors ... close, long-term relationships with their clients. Their consultative ... planning and objective setting, implementation, and monitoring. Their ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Helps with Back to School Preparation 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3
... The British Association for Psychopharmacology (BAP) has released fresh ... and addiction in the Journal of Psychopharmacology , ... researched the new, comprehensive guidelines, offering practitioners a detailed ... clinical decisions. The new BAP guidelines target treatment ...
... with intact proteins of the same kind, thereby triggering ... discovered by researchers from the RUB Heart and Diabetes ... Hendrik Milting in an interdisciplinary research project with colleagues ... report in the Journal of Biological Chemistry . ...
... , WEDNESDAY, May 23 (HealthDay News) -- The ... reduced through a multi-pronged approach that includes more training ... to a new German study. Despite legal regulations ... as bed rails and belts still are frequently used ...
... resilient metal wire designed to gather and compress diseased lung ... a subtype of the disease that involves specific, usually isolated ... multicenter international trial conducted in the Netherlands, Germany and France. ... be easily implanted and is designed to take the place ...
... imaging (MRI) provides an indication of a breast tumor,s ... clinical examination, according to a new study published online ... with breast cancer often undergo chemotherapy prior to surgery. ... known as neoadjuvant chemotherapy, are more likely to achieve ...
... Ill. -- Children born with cleft lip, cleft palate ... appearance. Patients can face serious airway, feeding, speech ... challenges, Laura Swibel Rosenthal, MD, of Loyola University Medical ... of Otolaryngologic Clinics of North America . ...
Cached Medicine News:Health News:British experts update addiction treatment guidelines 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Breast MRI helps predict chemotherapy's effectiveness 2Health News:Cleft lip/palate cause much more than cosmetic problems 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: